Clinical Utilization of Pharmacogenetics in Psychiatry –
                    Perspectives of Pharmacists, Genetic Counselors, Implementation Science,
                    Clinicians, and Industry

Lisa Brown; Seenae Eum; Susanne B. Haga; Jeffrey R. Strawn; Heather Zierhut

doi:10.1055/a-0975-9595

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2020; 53(04): 162-173
DOI: 10.1055/a-0975-9595

Review

Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

Lisa Brown

¹Myriad Neuroscience, Myriad Genetics Inc, Salt Lake City, United States

,

Seenae Eum

²Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, United States

,

Susanne B. Haga

³Duke University School of Medicine, Durham, United States

,

Jeffrey R. Strawn

⁴Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, United States

,

Heather Zierhut

²Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, United States

› Author Affiliations

Abstract

Introduction The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. PGx testing represents a decision support tool that may inform dosing, increase the likelihood of treatment response, and identify patients at risk for medication side effects.

Methods This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counselors, implementation scientists, industry, and clinicians.

Results While many limitations exist to streamline use of PGx testing in psychiatry, various stakeholders are crucial to clinical implementation.

Discussion PGx testing can assist in medication selection and improve patient outcomes; however, more data are needed to understand when and how to incorporate PGx testing into psychiatric practice.

Key words

pharmacogenomics - pharmacogenetics - implementation

Full Text

References

References
1 Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: A review. Can J Psychiatry 2010; 55: 126-135
2 Warden D, Rush AJ, Trivedi MH. et al. The STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep 2007; 9: 449-459
3 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
4 Ramsey LB, Prows CA, Zhang K. et al. Implementation of pharmacogenetics at Cincinnati Children’s Hospital Medical Center: Lessons learned over 14 years of personalizing medicine. Clin Pharmacol Ther 2019; 105: 49-52
5 Corponi F, Fabbri C, Serretti A. Pharmacogenetics in psychiatry. Adv Pharmacol 2018; 83: 297-331
6 Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: Update and clinical implications. Mol Neuropsychiatry 2018; 8: 1-26
7 International Society of Psychiatric Genetics (ISPG). Pharmacogenomics of Antipsychotic-Induced Weight Gain & Metabolic Syndrome. Available at https://www.pgrn.org/aiwg.html
8 Drozda K, Muller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014; 34: 166-184
9 Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: Clinical implications and considerations. Dialogues Clin Neurosci 2016; 18: 323-337
10 Food and Drug Administration (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling.Available at https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
11 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinic Pharmacol Ther 2015; 98: 127-134
12 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinic. Pharmacol Ther 2017; 102: 37-44
13 Hicks JK, Swen JJ, Thorn CF. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinic Pharmacol Ther 2013; 93: 402-408
14 Nassan M, Nicholson WT, Elliott MA. et al. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: A template for psychiatric precision medicine. Mayo Clin Proc 2016; 91: 897-907
15 Fan M, Bousman CA. Commercial pharmacogenetic tests in psychiatry: Do they facilitate the implementation of pharmacogenetic dosing guidelines? Pharmacopsychiatry. 2019; Mar 21 [Epub ahead of print]
16 Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet Genomics 2017; 27: 387-393
17 Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7: 9-37
18 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
19 Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239-258
20 Phillips EJ, Sukasem C, Whirl-Carrillo M. et al. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther 2018; 103: 574-581
21 Preskorn SH, Kane CP, Lobello K. et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: Implications for personalized medicine. J Clin Psychiatry 2013; 74: 614-621
22 Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol 2015; 79: 222-240
23 Crews KR, Cross SJ, McCormick JN. et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011; 68: 143-150
24 Centers for Disease Control and Prevention (CDC). Advancing Team-Based Care Through Collaborative Practice Agreements: A Resource and Implementation Guide for Adding Pharmacists to the Care Team. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services 2017
25 Tanner JA, Davies PE, Voudouris NC. et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. J Psychiatr Res 2018; 104: 157-162
26 Bousman CA, Arandjelovic K, Mancuso SG. et al. Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. Pharmacogenomics 2019; 20: 37-47
27 Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord 2018; 241: 484-491
28 Greden JF, Parikh SV, Rothschild AJ. et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 2019; 111: 59-67
29 Perez V, Salavert A, Espadaler J. et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 2017; 17: 250
30 Bradley P, Shiekh M, Mehra V. et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res 2018; 96: 100-107
31 Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 2015; 13: 150-156
32 Winner JG, Carhart JM, Altar CA. et al. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 2013; 16: 219-227
33 Hall-Flavin DK, Winner JG, Allen JD. et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013; 23: 535-548
34 Hall-Flavin DK, Winner JG, Allen JD. et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012; 2: e172
35 Altar CA, Carhart J, Allen JD. et al. Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: Evidence from three clinical studies. Mol Neuropsychiatry 2015; 1: 145-155
36 Bousman CA, Muller DJ, Ng CH. et al. Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study. Pharmacogenet Genomics 2017; 27: 1-6
37 Olson MC, Maciel A, Gariepy JF. et al. Clinical impact of pharmacogenetic-guided treatment for patients exhibiting neuropsychiatric disorders: a randomized controlled trial. Prim Care Companion CNS Disord 2017; 19: 16m02036
38 Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe. BMC Medical Genomics 2017; 10: 47
39 Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff (Millwood) 2018; 37: 717-723
40 FDA. 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports. Available at https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180028.pdf
41 FDA. FDA Authorizes First Direct-to-Consumer Test for Detecting Genetic Variants That May Be Associated with Medication Metabolism. Available at https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-direct-consumer-test-detecting-genetic-variants-may-be-associated-medication
42 FDA. The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications: FDA Safety Communication. Available at https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-many-genetic-tests-unapproved-claims-predict-patient-response-specific
43 FDA. FDA Issues Warning Letter to Genomics Lab for Illegally Marketing Genetic Test That Claims to Predict Patients’ Responses to Specific Medications. Available at https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-genomics-lab-illegally-marketing-genetic-test-claims-predict-patients
44 FDA. Warning Letter: Inova Genomics Laboratory. Available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inova-genomics-laboratory-577422-04042019
45 Bousman CA, Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 2018; 18: 613-622
46 PharmGKB Blog. CYP2C19 testing may assist with prescribing sertraline and escitalopram. Available at https://pharmgkb.blogspot.com/2019/04/cyp2c19-testing-may-assist-with.html
47 Huddart R, Sangkuhl K, Whirl-Carrillo M et al. Are randomized controlled trials necessary to establish the value of implementing pharmacogenomics in the clinic? Clin Pharmacol Ther 2019 April 12 [Epub ahead of print]
48 Ginsburg GS, Kuderer NM. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: A common bond. J Clin Oncol 2012; 30: 4233-4242
49 Dhanda DS, Guzauskas GF, Carlson JJ. et al. Are evidence standards different for genomic- vs. clinical-based precision medicine? A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther 2017; 102: 805-814
50 Frieden TR. Evidence for health decision making – beyond randomized, controlled trials. N Engl J Med 2017; 377: 465-475
51 Lu CY, Williams MS, Ginsburg GS. et al. A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. Genet Med 2018; 20: 390-396
52 National Institutes of Health (NIH). Comparative Effectiveness of Pharmacogenomics for Treatment of Depression (CEPIO-D). Available at https://clinicaltrials.gov/ct2/show/NCT03749629?term=cepio-d&rank=1
53 Zeier Z, Carpenter LC, Kalin NH. et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry 2018; 175: 873-886
54 Implementing Genomics in Practice (IGNITE). Implementing Genomics in Practice. Available at https://gmkb.org/ignite-ii-network-2/
55 Espadaler J, Tuson M, Lopez-Ibor JM. et al. Pharmacogenetic testing for the guidance of psychiatric treatment: A multicenter retrospective analysis. CNS Spectr 2017; 22: 315-324
56 Winner J, Allen JD, Altar CA. et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013; 3: e242
57 Benitez J, Cool CL, Scotti DJ. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med 2018; 15: 481-494
58 Brixner D, Biltaji E, Bress A. et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ 2016; 19: 213-228
59 Fagerness J, Fonseca E, Hess GP. et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care 2014; 20: e146-e156
60 Boland JR, Duffy B, Myer NM. Clinical utility of pharmacogenetics-guided treatment of depression and anxiety. Pers Med Psychiatry 2018; 7–8: 7-13
61 Blasco-Fontecilla H. Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders. J Neural Transm (Vienna) 2019; 126: 101-107
62 Perlis RH, Mehta R, Edwards AM. et al. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depress Anxiety 2018; 35: 946-952
63 Tonozzi TR, Braunstein GD, Kammesheidt A. et al. Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: A retrospective, cross-sectional study. Pharmacogenomics 2018; 19: 1169-1179
64 Arandjelovic K, Eyre HA, Lenze E. et al. The role of depression pharmacogenetic decision support tools in shared decision making. J Neural Transm (Vienna) 2019; 126: 87-94
65 Abbott R, Chang DD, Eyre HA. et al. Pharmacogenetic decision support tools: A new paradigm for late-life depression?. Am J Geriatr Psychiatry 2018; 26: 125-133
66 Ta R, Cayabyab MAS, Coloso R. Precision medicine: a call for increased pharmacogenomic education. Per Med 2019; 16: 233-245
67 Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: Barriers and solutions. J Pharm Sci 2017; 106: 2368-2379
68 Owusu Obeng A, Fei K, Levy KD. et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: A multi-site IGNITE-network survey. J Pers Med 2018; 8: 24
69 Stevenson JM. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy. Pharmacogenomics 2018; 19: 167-170
70 Giri J, Curry TB, Formea CM. et al. Education and knowledge in pharmacogenomics: Still a challenge?. Clin Pharmacol Ther 2018; 103: 752-755
71 Zierhut HA, Campbell CA, Mitchell AG. et al. Collaborative counseling considerations for pharmacogenomic tests. Pharmacotherapy 2017; 37: 990-999
72 Goehringer JM, Bonhag MA, Jones LK. et al. Generation and implementation of a patient-centered and patient-facing genomic test report in the EHR. EGEMS (Wash DC) 2018; 6: 14
73 Graham R, Mancher M, Miller Wolman D. et al. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academy Press; 2011
74 ISPG. Genetic Testing and Psychiatric Disorders. Available at https://ispg.net/genetic-testing-statement/
75 American Society of Health-System Pharmacists (ASHP). ASHP statement on the pharmacist’s role in clinical pharmacogenomics. Am J Health Syst Pharm 2015; 72: 579-581
76 Kennedy MJ. Personalized medicines – are pharmacists ready for the challenge?. Integr Pharm Res Pract 2018; 7: 113-123
77 Crabtree B, Bootman JL, Boyle CJ. et al. Aligning the AACP strategic engagement agenda with key federal priorities in health: Report of the 2016–17 Argus Commission. Am J Pharm Educ 2017; 81: S15-S15
78 Resta R, Biesecker BB, Bennett RL. et al. A new definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force report. J Genet Couns 2006; 15: 77-83
79 Valderrama J, Pato C, Pato M. A relationship between early life stress and depression-the role of SLC6A4 5-HTTLPR. Int J Ment Health. Psychiatry 2017; 4: S09
80 Inglis A, Koehn D, McGillivray B. et al. Evaluating a unique, specialist psychiatric genetic counseling clinic: Uptake and impact. Clin Genet 2015; 87: 218-224
81 Mukerjee G, Huston A, Kabakchiev B. et al. User considerations in assessing pharmacogenomic tests and their clinical support tools. NPJ Genom Med 2018; 3: 26
82 Mallal S, Phillips E, Carosi G. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579
83 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362
84 Elliott LS, Henderson JC, Neradilek MB. et al. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One 2017; 12: e0170905
85 Ruzzo A, Graziano F, Galli F. et al. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 2017; 117: 1269-1277
86 Kimmel SE, French B, Kasner SE. et al. A pharmacogenetic vs. a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283-2293
87 Pirmohamed M, Burnside G, Eriksson N. et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294-2303
88 Limdi NA, Brown TM, Yan Q. et al. Race influences warfarin dose changes associated with genetic factors. Blood 2015; 126: 539-545
89 Ioannidis JP. To replicate or not to replicate: The case of pharmacogenetic studies: Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?. Circ Cardiovasc Genet 2013; 6: 413-418
90 Hubacek JA, Dlouha D, Adamkova V. et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 2015; 21: 1454-1459
91 Walden LM, Brandl EJ, Tiwari AK et al. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Res 2018 Mar 9 [Epub ahead of print]
92 Brennan FX, Gardner KR, Lombard J. et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord 2015; 17
93 Manworren RC, Jeffries L, Pantaleao A. et al. Pharmacogenetic testing for analgesic adverse effects: pediatric case series. Clin J Pain 2016; 32: 109-115
94 Del Re M, Latiano T, Fidilio L. et al. Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment. EPMA J 2017; 8: 69-73
95 Arellano AL, Martin-Subero M, Monerris M. et al. Multiple adverse drug reactions and genetic polymorphism testing: a case report with negative result. Medicine (Baltimore) 2017; 96: e8505
96 Tong CC, Lam CW, Lam KO. et al. A novel DPYD variant associated with severe toxicity of fluoropyrimidines: role of pre-emptive DPYD genotype screening. Front Oncol 2018; 8: 279
97 Van Driest SL, Shi Y, Bowton EA. et al. Clinically actionable genotypes among 10 000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther 2014; 95: 423-431
98 Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 2014; 15: 655-665
99 Abaji R, Gagne V, Xu CJ. et al. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget 2017; 8: 43752-43767
100 Gasso P, Rodriguez N, Boloc D. et al. Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry 2017; 77: 236-240
101 Antoniazzi S, Tatulli A, Falvella FS. et al. The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: A case report. J Clin Pharm Ther 2017; 42: 119-121
102 Eum S, Schneiderhan ME, Brown JT. et al. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: A case report. BMC Psychiatry 2017; 17: 238
103 Ferreri SP, Greco AJ, Michaels NM. et al. Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) 2014; 54: 172-180
104 Dunnenberger HM, Crews KR, Hoffman JM. et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2015; 55: 89-106
105 Volpi S, Bult CJ, Chisholm RL. et al. Research directions in the clinical implementation of pharmacogenomics: An overview of US programs and projects. Clin Pharmacol Ther 2018; 103: 778-786
106 Arnall JR, Petro R, Patel JN. et al. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice. J Oncol Pharm Pract 2019; 25: 179-186
107 Caraballo PJ, Bielinski St SJ, Sauver JL. et al. Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clin Pharmacol Ther 2017; 102: 254-264
108 Accreditation Council for Pharmacy Education (ACPE). Accreditation Standards and Guidelines: Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree 2015
109 Frick A, Benton C, Suzuki O. et al. Implementing clinical pharmacogenomics in the classroom: Student pharmacist impressions of an educational intervention including personal genotyping. Pharmacy (Basel, Switzerland). 2018: 6-115
110 Adams SM, Anderson KB, Coons JC. et al. Advancing pharmacogenomics education in the core PharmD curriculum through student personal genomic testing. Am J Pharm Educ 2016; 80: 3
111 Devine EB, Lee CJ, Overby CL. et al. Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach. Int J Med Inform 2014; 83: 473-483
112 Herr TM, Peterson JF, Rasmussen LV. et al. Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network. J Am Med Inform Assoc 2019; 26: 143-148
113 Hull LE, Lynch KG, Oslin DW. VA primary care and mental health providers’ comfort with genetic testing: Survey results from the PRIME care study. J Gen Intern Med 2019; 34: 799-801
114 Nurnberger Jr JI, Austin J, Berrettini WH. et al. What should a psychiatrist know about genetics? Review and recommendations from the residency education committee of the International Society of Psychiatric Genetics. J Clin Psychiatry 2018; 80: 17nr12046
115 McMichael AJ, Boeri M, Rolison JJ. et al. The influence of genotype information on psychiatrists’ treatment recommendations: More experienced clinicians know better what to ignore. Value Health 2017; 20: 126-131
116 Amara N, Blouin-Bougie J, Bouthillier D. et al. On the readiness of physicians for pharmacogenomics testing: An empirical assessment. Pharmacogenomics J 2018; 18: 308-318
117 Walden LM, Brandl EJ, Changasi A. et al. Physicians’ opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res 2015; 229: 913-918
118 Dunlop B, Rakofsky J. Surveying psychiatrists’ psychopharmacology practices across common clinical scenarios. FOCUS 2017; 15: 445-449
119 Cservenka A, Yardley MM, Ray LA. Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. Am J Addict 2017; 26: 516-525
120 Rajman I, Knapp L, Morgan T. et al. African genetic diversity: Implications for cytochrome P450-mediated drug metabolism and drug development. EBioMedicine 2017; 17: 67-74
121 Hoop JG, Lapid MI, Paulson RM. et al. Clinical and ethical considerations in pharmacogenetic testing: Views of physicians in 3 “early adopting” departments of psychiatry. J Clin Psychiatry 2010; 71: 745-753
122 Strawn JR, Geracioti L, Rajdev N. et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018; 19: 1057-1070
123 Strawn JR, Welge JA, Wehry AM. et al. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta-analysis. Depress Anxiety 2015; 32: 149-157
124 Rahman T, Ash DM, Lauriello J. et al. Misleading guidance from pharmacogenomic testing. Am J Psychiatry 2017; 174: 922-924
125 Bousman C, Allen J, Eyre HA. Pharmacogenetic tests in psychiatry. Am J Psychiatry 2018; 175: 189
126 Aldrich SL, Poweleit EA, Prows CA. et al. Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol 2019; 10: 1-12
127 Strawn JR, Poweleit EA, Ramsey LB. CYP2C19-guided escitalopram and sertraline dosing in pediatric patients: A pharmacokinetic modeling study. J Child Adolesc Psychopharmacol 2019; 29: 340-347
128 Fohner A, Muzquiz LI, Austin MA. et al. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics 2013; 23: 403-414
129 Maruf AA, Greenslade A, Arnold PD. et al. Antidepressant pharmacogenetics in children and young adults: A systematic review. J Affect Disord 2019; 254: 98-108
130 Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: Strategies and opportunities for personalized psychiatry. EPMA J 2017; 8: 211-227
131 Peterson K, Dieperink E, Ferguson L. et al. VA Evidence Synthesis Program Reports-Evidence Brief: The Comparative Effectiveness, Harms, and Cost-Effectiveness of Pharmacogenomics-Guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder, in VA Evidence Synthesis Program Evidence Briefs. Washington, DC: Department of Veterans Affairs; 2011
132 Chang DD, Eyre HA, Abbott R. et al. Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life. Pharmacogenomics 2018; 19: 1269-1284
133 NIH. ClinicalTrials.gov.Available at https://clinicaltrials.gov/
134 Bousman C, Maruf AA, Muller DJ. Towards the integration of pharmacogenetics in psychiatry: A minimum, evidence-based genetic testing panel. Curr Opin Psychiatry 2019; 32: 7-15
135 Brown JT, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther 2019; 106: 94-102
136 Leckband SG, Kelsoe JR, Dunnenberger HM. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94: 324-328
137 Caudle KE, Rettie AE, Whirl-Carrillo M. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014; 96: 542-548